Session Details

Speakers, titles, times, and locations of ASGCT presentations

Detailed Program

Friday, May 10 2024
04:15 PM – 04:30 PM ET - Ballroom 1

333: First in Class ASO Targeting IGHMBP2 Cryptic Splice Variant: Efficacy and Safety

Sandra Smieszek - PhD
Vanda Pharmaceuticals Inc.

Disclosures:   S.P. Smieszek: 1; Commercial Interest i.e. Company X; employee VANDA.

Related Abstract

© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy. 

Kentico CMS Development by Reason One | Powered by Kentico

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.